Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Core Insights - NeOnc Technologies Holdings, Inc. is a clinical-stage CNS oncology company focused on developing therapies to improve drug delivery to the brain, specifically targeting the blood-brain barrier (BBB) [1] - The company's lead program, NEO212, is a next-generation version of temozolomide (TMZ) aimed at addressing limitations in current treatments for brain cancer, particularly in glioblastoma [1] - NeOnc's platform includes additional programs like NEO100, which utilizes intranasal delivery methods to enhance drug penetration in the CNS [1] Company Developments - NEO212 has completed Phase 1 dose escalation in recurrent glioblastoma, establishing a Recommended Phase 2 Dose of 610 mg, with early signs of disease control observed [6] - NEO100 has shown promising Phase 2 data, indicating radiographic responses and improved progression-free survival compared to historical benchmarks [6] - NeOnc recently completed a successful PIPE offering, adding a gross $16.0 million to its balance sheet, enhancing its financial position for further development [1]